OHCA Provider Letter 2020-03 Prior authorization of Lumoxiti– Effective Aug 1, 2020

As authorized by Oklahoma Administrative Code (OAC)  317:30-5-77.2, effective Aug 1, 2020, the Oklahoma Health Care Authority (OHCA) will be adding a prior authorization requirement for Lumoxiti® (moxetumomab pasudotox-tdfk).

Please view the Provider Letter in its entirety here: Provider Letter 2020-03.

Submit all comments by close of business, Aug 3, 2020, via the comment box below.




Name (optional)

Email (optional)



Please note that all comments must be reviewed and approved prior to posting. Approved comments will be posted Monday through Friday between the hours of 7:30 a.m. – 4 p.m. Any comments received after 4 p.m. will be posted on the following business day.